NTRA · Natera, Inc.
$309.93
-0.85 (-0.27%)
At close · Aug 14
Market Cap
$44.67B
Shares
144.14M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$309.93
Open$308.01
Day$305.00–311.99
52W close$158.44–322.10
Avg vol 30d1.3M
Short int4.4M · 3.0% float · 4.7d
Short vol55%
Last earningsAug 6, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 7
Up next
Next earnings call
Nov 5, 2026
Est · unconfirmed
· in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 7, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+37%
above
Price vs 50-day avg
+18%
above
RSI (14)
66
neutral
MACD trend
Positive
52-week position
93%
near high
Momentum
relative strength
1-month return
+14%
trailing
6-month return
+48%
trailing
YTD return
+35%
this year
Relative strength
+34%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $262 › 200d $226 — 50d above 200d
Institutional flow
Accumulating
+9% holders QoQ · +156 funds added
Insider flow
Distributing
Net -$19.6M over 90 days · 100% sells
Short interest
Falling
3.03% of float · ▼ -12.1% MoM · 4.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
837 holders — near 3-yr high, broad support
Squeeze score
63
elevated · 0–100
Fundamentals
Revenue growth
−3%
Y/Y
EPS growth
+1%
Y/Y
Free cash flow
$109.1M
Balance sheet
$102.7M
net cash
Quant / Vol
risk profile
Volatility
48%
annualized · 1-yr
Max drawdown
−28%
past year
ATR
4.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 6, 2026
Total revenue
· 2026
$2.85B – $2.91B
prior FY $2.31B
midpoint +24.9% Y/Y
Selling, general and administrative costs
· 2026
$1.13B – $1.23B
Gross margin
· 2026
64% – 66%
Research and development costs
· 2026
$800M – $900M
R&D expense
· 2026
$800M – $900M
Prior guidance
period ended
· from the 8-K filed Nov 6, 2025
Total revenue
· 2025
$2.18B – $2.26B
Net cash inflow
· 2025
$100M
Selling, general and administrative costs
· 2025
$1.08B – $1.18B
Research and development costs
· 2025
$575M – $625M
Gross margin
· 2025
62% – 64%
Gross margin
· 2025
62% – 64%
Guided vs delivered
· last 2 settled
Total revenue
2025
guided $2.18B – $2.26B
$2.31B
Beat +3.9%
Revenues
for the rest of the year
guided $1.42B – $1.45B
$1.7B
Beat +18.3%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+37%
Bullish
Price vs 50-day avg
+18%
Bullish
RSI (14)
66
Neutral
MACD trend
Positive
Bullish
52-week position
93%
Bullish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $262 › 200d $226 — 50d above 200d
Institutional flow
Accumulating
+9% holders QoQ · +156 funds added
Insider flow
Distributing
Net -$19.6M over 90 days · 100% sells
Short interest
Falling
3.03% of float · ▼ -12.1% MoM · 4.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
837 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $158
Now $310 · 93%
Range high $322
vs 200-day avg +37%
vs 50-day avg +18%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Gross margin % | 64.5% | FY26 Q2 | — |
|
|
|||
| Oncology tests processed | 296,700 | Q2 2026 | — |
|
|
|||
| Tests accessioned | 1,030,100 | Q2 2026 | — |
|
|
|||
| Tests processed | 1,043,900 | Q2 2026 | — |
|
|
|||
| Tests reported | 985,500 | Q2 2026 | — |
|
|
|||
| Tests reported in our laboratory | 972,000 | Q2 2026 | — |
|
|
|||
| Non-GAAP cash inflow non-GAAP | $100M | full year 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NTRA
this stock
Natera, Inc.
|
$44.67B | +35.3% | -2.8% | — | 3.0% |
|
TMO
Thermo Fisher Scientific Inc.
|
$217.52B | +1.5% | +14.5% | 31.7 | 1.3% |
|
DHR
Danaher Corp /De/
|
$142.32B | -11.6% | +8.5% | 35.9 | 1.7% |
|
IDXX
Idexx Laboratories Inc /De
|
$43.41B | -18.6% | +10.4% | 38.7 | 2.4% |
|
A
Agilent Technologies, Inc.
|
$41.95B | +9.2% | +6.4% | 29.8 | 2.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NTRA | -3.8% | +14.2% | +48.0% | +15.8% | +35.3% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -4.2% | +9.8% | +34.3% | +11.8% | +21.4% |
Key facts
CIK
1604821
CUSIP
632307104
13F (30d)
777 filings
752 filers
Visit website
Investor relations